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Fig. 1. The possibility of translating traditional Chinese medicine (TCM) into therapy of chronic liver diseases (CLD). The merger of holistic TCM with the more particularistic 
and complementary views of Western medicine holds promise for the development of novel drugs for CLD including liver fibrosis. Implementation of cutting-edge technologies and 
rigorous study design should finally create innovation and synergism. Shown are examples of TCM drugs and their cellular activities relevant for liver inflammation and fibrosis. 
Implementation of cutting-edge technologies and rigorous study design should finally create innovation and synergism. MΦ: macrophage; HSC, hepatic stellate cell; HEP, hepatocyte.
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Formulas Patients
(trial design)
Diseases Duration
(wk)
Parameters improved Reference
Compound 861 102 (RC) Early stages of cirrhosis, 
liver ﬁ brosis with CHB
24 Liver function, serum ﬁ brosis markers, inﬂ ammatory 
and necrosis grade
Yin SS, et al., 
Chin J Hepatol 2004
Biejiaruangan compound 104 (RC) Cirrhosis with CHB 24 Serum ﬁ brosis markers, size of portal vein and spleen Gao GF, et al., 
Chin J Clin Hepatol 2006
Fuzhenghuayu capsule 216 (RC) Liver ﬁ brosis with CHB 24 Liver function, serum ﬁ brosis markers, inﬂ ammatory 
grade
Liu P, et al., 
World J Gastroenterol 2005
Qiang gan ruan jian Tang 38 Cirrhosis with CHB, and/
or CHC
12 Liver function, ascites levels, symptoms of cirrhosis Wang ZW.
J Military Sur Southwest China 2009
Qiang gan ruan jian Fang 62 (RC) Cirrhosis with CHB and/or 
schistosomiasis
12 Serum ﬁ brosis markers, size of portal and splenic vein Wang XS, et al., 
Shanghai J Tradit Chin Med 2003
Qiang gan ruan jian Wan 70 (RC) Cirrhosis with CHB and 
splenomegaly
5 Liver function, size of portal vein and spleen Shi HL, et al., 
Jilin J Tradit Chin Med 2006
Qianggan capsule 88 (RC) Non-alcoholic fatty liver 
disease
24 Liver function, serum TG level, liver/spleen ratio Li L, et al., 
Chin J Integr Med 2010
Qianggan capsule 63 (RC) Liver ﬁ brosis with CHB 24 Serum ﬁ brosis markers, inﬂ ammation and necrosis Yang LM, et al., 
Chin J Integr Med 2002
Qianggan capsule 60 Non-alcoholic fatty liver 
disease
12 Liver function, serum TC, TG, HDL-C levels, liver/
spleen ratio
Zhang W, et al., 
Shanghai J Tradit Chin Med 2007
Qianggan capsule 80 (RC) Liver ﬁ brosis with CHB 16 Liver function, serum ﬁ brosis markers Xue GQ, et al., 
Shandong J Tradit Chin Med 2004
Yi gan kang 365 (RC) Liver ﬁ brosis with CHB 24 Serum ﬁ brosis markers, liver function, size of liver and 
spleen
Yao HS, et al., 
Clin Focus 2009
Yi gan kang 116 (RC) CHB 16-24 Liver function, percussion tenderness, HBeAg and/or 
HBV-DNA
Jia SY, et al., 
Chin Remedies & Clinics 2007
Yi gan kang 180 (RC) CHB 24 Liver function, percussion tenderness, size of liver and 
spleen, HBV-DNA, HBeAg, HBsAg
Han FY, et al., 
Chin Cummunity Doctors 2012
Jian pi bu shen Fang 50 (RC) Cirrhosis complicated by 
hepatorenal syndrome
3 Liver function, renal function Tang G, et al., 
Mod Tradit Chin Med 2013
Only the 3 major ingredients are listed. Compound 861: Salvia miltiorrhiza, Radix Astragali, Cordyceps; Biejiaruangan Compound: Carapax trionycis, Panax pseudoginseng, Radix Paeoniae 
Rubra; Fuzhenghuayu Capsule: Salviae miltiorrhizae, Cordyceps, Semen Persicae; Qiang gan ruan jian Tang: Salvia miltiorrhiza, Radix Astragali, Carapax trionycis; Qiang gan ruan jian 
Fang: Codonopsis pilosula, Angelica sinensis, Carapax trionycis; Qiang gan ruan jian Wan: Radix Astragali, Carapax trionycis, Manis pentadactyla; Qianggan Capsule: Salvia miltiorrhiza, 
Radix Astragali, Codonopsis pilosula; Yi gan kang: Angelica sinensis, Radix Astragali, Salvia miltiorrhiza; Jian pi bu shen Fang: Radix Astragali, Salvia miltiorrhiza, Atractylodes macro-
cephala.
RC, randomized controlled; CHB, chronic hepatitis B; CHC, chronic hepatitis C; TG, triglycerides; TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol.
Table 1. Clinical studies on the efficacy of TCM in the treatment of CLD. Therapies that specifically retard progression or induce regression 
of fibrotic liver disease have entered the clinical stage [1,2]. This is 
remarkable, since clinical validation of antifibrotic efficacy remains 
difficult and since the mere reduction of excess scarring, without an 
improvement of hepatic angio-architecture and synthetic function 
is a disputed primary clinical endpoint [3]. Importantly, as in cancer 
therapies, drugs that address more than a single pathogenic pathway 
are usually more efficient than single highly specific pathway 
modulators [1]. Moreover, the high costs and risks of drug development 
have opened the field for drug repurposing, i.e., the validation and 
use of defined agents that were already tested clinically for diseases 
other than fibrosis. These insights have further sparked an interest in 
a more holistic pharmacological approach to fibrosis, which includes 
reevaluation of the herbs of Traditional Chinese Medicine (TCM).
   The recorded history of TCM can be traced back over 2000 years, 
although it is common belief that its origins range as far back as 
Chinese civilization, i.e., >5000 years. TCM derived its theoretical 
foundations, including diagnostic and treatment methodologies, from 
ancient Chinese philosophy. It virtually dragged the Chinese nation 
through periods of poverty and chaos as an exclusive medical way of 
health care, before Western medicine was introduced after a series of 
revolutionary campaigns in the 20th century.
   Unlike Western medicine, TCM strictly relies on the two therapeutic 
pillars of holism and syndrome differentiation. In this system, the 
human body is not simply regarded as an entity in which different parts 
work interdependently but also a portion of the universe in which it is 
embedded and with which it interacts. Sickness is triggered by the 
imbalance of Yin and Yang, a concept of contrary but complementary 
forces in nature, resulting in various symptoms with a dynamic trend 
in the course of disease. Here, holistic but individualized approaches 
that use herbal remedies are targeted at the complex syndrome, to 
help the body regain balance and harmony.
   Chronic liver diseases (CLD) have never been described as such 
in written documentations of TCM. Therefore, it has been difficult 
to establish a precise description of CLD in modern TCM, and 
symptomatic terms such as abdominal swelling, yellow skin and right Journal of Hepatologyupper abdominal pain were included only in the 1970s [4]. Thereafter, 
the definition of CLD in TCM was gradually refined to encompass: (1) 
Weakening of the Qi (biological substances/activities that preserve life); 
(2) blockage of meridians (circulation channels of Qi) by blood stasis; 
(3) generation of dampness and heat (inflammatory pathogens) [5]. 
Only then studies began to systematically examine the effect of TCM 
on defined CLD [6]. Major aims were the eradication or suppression 
of the underlying cause of CLD, such as HBV or HCV infection, and 
treatment of its hard endpoints, cirrhosis and HCC, with a major focus 
on fibrosis. However, there remained problems to reconcile TCM, 
which traditionally valued empiricism and holistic philosophy, with the 
Western approach to CLD, such as a reproducible standardization 
of herbs using quantifiable lead compounds (biologically active 
ingredients), the frequent lack of rigorous stratification of patients or 
absence of a double-blind, randomized, placebo-controlled clinical 
trial design. Moreover, mechanistic preclinical validation of TCM drugs 
is still in its infancy, with a focus on select cultures of liver cells and 
cell lines, and a relatively narrow spectrum of in vivo rodent models 
of liver inflammation and fibrosis. Finally, some TCM drugs have been 
accused of negligent safety evaluation, based on case reports of 
hepatotoxicity or nephrotoxicity [7], largely due to contamination with 
heavy metals or toxic alkaloids. However, the Chinese government 
has begun to initiate a national safety plan in 2011, investing in 
the modernization of TCM ($100 million from the National Natural 
Science Foundation in 2012), to promote research on lead compound 
identification and mechanisms of action, on a better standardization 
and well controlled clinical trials.
   Thus numerous clinical trials, some of them NIH-registered, were 
initiated and several formulations received approval by the China 
Food and Drug Administration. Approved and broadly marketed anti-
fibrotic formulations are: Compound 861, an aqueous extract of 10 
herbs targeting blood stasis and liver stagnation [8]; Biejiaruangan 
Compound (CBJRGC), a prescription containing Carapax trionycis 
(turtle shell) and 10 herbs to soften the liver [9]; Fuzheng Huayu 
(FZHY), consisting of six herbs, to resolve blood stasis and nourish 
the liver [10]. Both CBJRBC and FZHY reached sales >$30 million  2014 vol  61 | 166–168 167
during 2012 in China, and an antifibrotic effect of FZHY has been 
suggested in a recently completed US FDA-approved trial in patients 
with chronic hepatitis C [11]. Table 1 lists major published studies on 
TCM for the treatment of liver fibrosis.
   Predictably, TCM should provide a rich resource for developing 
anti-inflammatory, anti-infectious, and anti-fibrotic drug candidates. 
A major challenge is its reconciliation with Western medicine, 
requiring translation of the TCM codes into a more scientific 
language, and identification of effective lead compounds in the 
heterogeneous herbal mixtures or extracts. The latter has already 
been achieved in some cases, revealing, e.g., interesting plant-
derived polyphenols, flavonoids or alkaloids that serve as antivirals, 
antioxidants or anti-fibrotics, often affecting different liver cells and 
signaling pathways (Fig. 1). However, identification of single active 
components partly contradicts the holistic theory of TCM which 
postulates that active ingredients and herbs will not work in isolation, 
a paradigm that reemerges even in Western medicine. An example 
is the appreciation of, e.g., the combined effect of nutrition, the 
intestinal microbiome, and physical exercise on metabolic, liver, and 
cardiovascular health [12]. Nonetheless, a valid compromise is to 
test individual compounds in isolation and then recombine agents 
with proven efficacy.
   Controversies how to further develop TCM are ongoing in China. 
One group deplores the modernization of TCM as submission to 
Western rules, the other group demands its continuing overhaul. 
There is also a concern of deteriorating drug quality, including 
contaminants accumulating in cultured herbs. Moreover, many 
young practitioners feel that adherence to TCM will compromise 
their career, and patients, especially in the cities, are increasingly 
skeptical about the efficacy of TCM. Still there is an overwhelming 
consensus that implementation of methodological improvements 
and rigorous scientific testing along the principles of evidence-based 
medicine will help to exploit the vast potential of TCM.
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